Lilly Investing In Future, But Staying Out Of The Biotech 'Bubble'
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm exceeds expectations in the second quarter, but is content to rely on in-house prospects for growth and take a measured approach to deal-making rather than jumping into the fray for the “hot property of the moment.”